<DOC>
	<DOCNO>NCT01323946</DOCNO>
	<brief_summary>The objective study evaluate immunogenicity safety prime-boost vaccination schedule GSK Biologicals ' investigational vaccine GSK1562902A .</brief_summary>
	<brief_title>Study Evaluate Immunogenicity Safety Investigational Pandemic Influenza Vaccine Children</brief_title>
	<detailed_description>This protocol post modify accord protocol amendment 2 ( date 16-June-2011 ) . The impacted section eligibility criterion .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe parents/Legally Acceptable Representatives ( LARs ) comply requirement protocol . Children , male female , include , 6 35 month age time first study vaccination . Written inform consent obtain parent ( ) /LAR ( ) subject . Healthy child establish medical history clinical examination enter study . Parent/LAR access consistent mean telephone contact , land line mobile , NOT pay phone multipleuser device . Subjects likely reside vicinity study centre duration study . In study use homebased model vaccination followup , subject likely remain vicinity area recruit . Use investigational nonregistered product study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period . Chronic administration immunosuppressant immunemodifying drug within six month prior first vaccine dose . Planned administration vaccine 30 day prior 21 day study vaccine administration . History reaction hypersensitivity likely exacerbate component vaccine egg protein thiomersal . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination . History neurological disorder seizure . Acute disease time enrolment . Acute chronic , clinically significant pulmonary , cardiovascular , hepatic renal functional abnormality , determine physical examination laboratory test . Administration immunoglobulins and/or blood product within three month prior enrolment study , plan administration study period . Any condition , opinion investigator , render subject unfit participation study . Child care . Previous vaccination time H5N1 vaccine . Medical history physicianconfirmed infection H5N1 virus .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>35 Months</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>H5N1</keyword>
	<keyword>influenza infection</keyword>
	<keyword>Influenza vaccine GSK1562902A</keyword>
</DOC>